[go: up one dir, main page]

FR2898358B1 - ASSOCIATION OF 5HT2 RECEPTOR ANTAGONIST AND 5HT2 RECEPTOR ACTIVATOR BY ALLOSTERIC MODULATION AND USES THEREOF AS MEDICAL PRODUCTS - Google Patents

ASSOCIATION OF 5HT2 RECEPTOR ANTAGONIST AND 5HT2 RECEPTOR ACTIVATOR BY ALLOSTERIC MODULATION AND USES THEREOF AS MEDICAL PRODUCTS

Info

Publication number
FR2898358B1
FR2898358B1 FR0602057A FR0602057A FR2898358B1 FR 2898358 B1 FR2898358 B1 FR 2898358B1 FR 0602057 A FR0602057 A FR 0602057A FR 0602057 A FR0602057 A FR 0602057A FR 2898358 B1 FR2898358 B1 FR 2898358B1
Authority
FR
France
Prior art keywords
receptor
association
medical products
allosteric modulation
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0602057A
Other languages
French (fr)
Other versions
FR2898358A1 (en
Inventor
Jean Bernard Fourtillan
Marianne Fourtillan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macef SAS
Original Assignee
Macef SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macef SAS filed Critical Macef SAS
Priority to FR0602057A priority Critical patent/FR2898358B1/en
Priority to PCT/EP2007/052117 priority patent/WO2007101863A1/en
Publication of FR2898358A1 publication Critical patent/FR2898358A1/en
Application granted granted Critical
Publication of FR2898358B1 publication Critical patent/FR2898358B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0602057A 2006-03-08 2006-03-08 ASSOCIATION OF 5HT2 RECEPTOR ANTAGONIST AND 5HT2 RECEPTOR ACTIVATOR BY ALLOSTERIC MODULATION AND USES THEREOF AS MEDICAL PRODUCTS Expired - Fee Related FR2898358B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0602057A FR2898358B1 (en) 2006-03-08 2006-03-08 ASSOCIATION OF 5HT2 RECEPTOR ANTAGONIST AND 5HT2 RECEPTOR ACTIVATOR BY ALLOSTERIC MODULATION AND USES THEREOF AS MEDICAL PRODUCTS
PCT/EP2007/052117 WO2007101863A1 (en) 2006-03-08 2007-03-07 Therapeutic combination of a 5ht2 receptor antagonist and of a 5ht2 receptor activator

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0602057A FR2898358B1 (en) 2006-03-08 2006-03-08 ASSOCIATION OF 5HT2 RECEPTOR ANTAGONIST AND 5HT2 RECEPTOR ACTIVATOR BY ALLOSTERIC MODULATION AND USES THEREOF AS MEDICAL PRODUCTS

Publications (2)

Publication Number Publication Date
FR2898358A1 FR2898358A1 (en) 2007-09-14
FR2898358B1 true FR2898358B1 (en) 2008-05-30

Family

ID=37421046

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0602057A Expired - Fee Related FR2898358B1 (en) 2006-03-08 2006-03-08 ASSOCIATION OF 5HT2 RECEPTOR ANTAGONIST AND 5HT2 RECEPTOR ACTIVATOR BY ALLOSTERIC MODULATION AND USES THEREOF AS MEDICAL PRODUCTS

Country Status (2)

Country Link
FR (1) FR2898358B1 (en)
WO (1) WO2007101863A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5758395B2 (en) 2009-10-15 2015-08-05 ザ チルドレンズ メディカル センター コーポレイション Sepiapterin reductase inhibitors for the treatment of pain
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10744122B2 (en) 2015-02-04 2020-08-18 Soeur Josefa Menendez Transdermal therapeutic system containing valentonin and use thereof as a medicament
WO2020072675A1 (en) * 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0754183A1 (en) * 1994-04-07 1997-01-22 Cemaf Novel spiro[indole-pyrrolidine] derivatives as melatoninergic agonists, method for preparing same and use thereof as a drug
FR2724384B1 (en) * 1994-09-14 1999-04-16 Cemaf NOVEL 3,4-DIHYDRO BETA-CARBOLINE DERIVATIVES OF MELATONIN AGONISTS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
FR2737725B1 (en) * 1995-08-08 1997-10-31 Valentonine NOVEL ACYLATED DERIVATIVES OF MELATONIN AND MELATONINERGIC ANALOGS, THEIR PREPARATION PROCESS AND THEIR USE AS MEDICAMENTS
FR2792937B1 (en) * 1999-04-27 2001-08-10 Cemaf NOVEL PYRROLO- (3,4-b) QUINOLEINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS

Also Published As

Publication number Publication date
WO2007101863A1 (en) 2007-09-13
FR2898358A1 (en) 2007-09-14

Similar Documents

Publication Publication Date Title
EP2528441A4 (en) CERTAIN KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
EP2637502A4 (en) SELECTIVE EGFR INHIBITORS OF A MUTANT AND USES THEREOF
IL210582A (en) Deuterated cycloalkyl- and tetrahydropyranyl- benzylbenzene derivatives, their pharmaceutical compositions and methods of use
EP2736337A4 (en) CERTAIN KYNURENIN-3-MONO-OXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
IL210843A0 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2219671A4 (en) USE OF TAM RECEPTOR INHIBITORS AS TAM IMMUNOSTIMULATORS AND ACTIVATORS AS IMMUNOSUPPRESSANTS
EP2640709A4 (en) AMIDE HYDROXYPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN DEACETYLASE AND METHODS OF USE
EP2751086A4 (en) KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
EP2615981A4 (en) IN SITU TRAINING OF HEMOSTATIC FOAM IMPLANTS
ZA200904211B (en) Compositions, synthesis and methods of using indanone based cholinesterase inhibitors
IL182527A0 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
EP2283358A4 (en) IMMUNOMODULANT COMPOSITIONS AND METHODS OF USE
EP2405758A4 (en) METHODS AND COMPOSITIONS FOR LIPOSOMAL FORMULATION OF ANTIGENS AND USES THEREOF
EP1981541A4 (en) Methods and compositions of targeted drug development
EP2400968A4 (en) COMPOSITION, SYNTHESIS AND METHODS OF USE OF ARYLPIPERAZINE DERIVATIVES
EP2582664A4 (en) PHENYLTHIOACETATES, COMPOSITIONS AND METHODS OF APPLICATION
EP2750677A4 (en) KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
MY151986A (en) Adamantyl diamide derivatives and uses of same
EP2503887A4 (en) SUBSTITUTED BIARYL DERIVATIVES AND METHODS OF USE
EP2170404A4 (en) COMPOSITIONS COMPRISING HUMAN EGFR RNASI AND METHODS OF USE
ZA200807680B (en) Small-molecule modulators of trp-p8 activity
WO2009051718A3 (en) Calcium receptor modulating agents
EP2386553A4 (en) BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
FR2898358B1 (en) ASSOCIATION OF 5HT2 RECEPTOR ANTAGONIST AND 5HT2 RECEPTOR ACTIVATOR BY ALLOSTERIC MODULATION AND USES THEREOF AS MEDICAL PRODUCTS
MX2012011382A (en) New polymorph.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20091130